Mergers & Acquisitions - Cardiome Pharma, Anti-virals

Filter

Popular Filters

1 to 25 of 1229 results

OPKO to buy Israel’s Inspiro, gaining rights to new drug delivery technology

18-04-2014

US biopharma company OPKO Health has entered into a definitive agreement to acquire Inspiro Medical an…

Inspiro MedicalMergers & AcquisitionsOPKO HealthPharmaceuticalRespiratory and Pulmonary

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

17-04-2014

Family-owned US chemical developer and manufacturer SI Group has signed a deal to acquire the antioxidants,…

AlbemarleAnalgesiaibuprofenMergers & AcquisitionsPharmaceuticalUSA

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

Bio-Techne to acquire China’s PrimeGene

15-04-2014

Techne Corp (d/b/a Bio-Techne) says that its R&D Systems China subsidiary has entered into an agreement…

Bio-TechneBiotechnologyMergers & AcquisitionsPrimeGene Bio-Tech

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

10-04-2014

US antivirals major Gilead Sciences today announced positive findings from an open-label clinical trial…

Anti-viralsBiotechnologyGilead SciencesResearchSovaldi

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

Bristol-Myers Squibb files for US approval of daclatasvir and asunaprevir for hepatitis C

07-04-2014

US pharma major Bristol-Myers Squibb has submitted New Drug Applications with the US Food and Drug Administration…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirNorth AmericaPharmaceuticalRegulationUSA

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Sweden’s Meda rejects Mylan’s takeover overture

Sweden’s Meda rejects Mylan’s takeover overture

06-04-2014

After a day of rumor and speculation about a takeover approach from US generic firm Mylan, Swedish drugmaker…

GenericsMedaMergers & AcquisitionsMylan Laboratories

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera

03-04-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

1 to 25 of 1229 results

Back to top